...
search icon
atnm-img

Actinium Pharmaceuticals Inc, Common Stock

ATNM

ASQ

$1.38

+$0.18

(15%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$39.31M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
578.49K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.27
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.03 L
$10.24 H
$1.38

About Actinium Pharmaceuticals Inc, Common Stock

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameATNMSectorS&P500
1-Week Return9.52%-1.91%-4.4%
1-Month Return-7.38%-8.22%-10.77%
3-Month Return4.55%-5.01%-15.29%
6-Month Return-26.6%-10.62%-11.9%
1-Year Return-80.75%-3.17%2.9%
3-Year Return-79.88%1.04%20.61%
5-Year Return-73.71%37.23%84.18%
10-Year Return-98.47%81.65%144.64%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue622.00K1.14M1.03M81.00K-[{"date":"2020-12-31","value":54.37,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.03,"profit":true},{"date":"2023-12-31","value":7.08,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue447.00K524.00K699.00K790.00K-[{"date":"2020-12-31","value":56.58,"profit":true},{"date":"2021-12-31","value":66.33,"profit":true},{"date":"2022-12-31","value":88.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(447.00K)620.00K331.00K81.00K-[{"date":"2020-12-31","value":-72.1,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.39,"profit":true},{"date":"2023-12-31","value":13.06,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin(71.86%)54.20%32.14%100.00%-[{"date":"2020-12-31","value":-71.86,"profit":false},{"date":"2021-12-31","value":54.2,"profit":true},{"date":"2022-12-31","value":32.14,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses22.39M26.11M35.13M52.00M42.12M[{"date":"2020-12-31","value":43.06,"profit":true},{"date":"2021-12-31","value":50.21,"profit":true},{"date":"2022-12-31","value":67.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":81,"profit":true}]
Operating Income(22.39M)(24.96M)(34.10M)(51.92M)(42.12M)[{"date":"2020-12-31","value":-2239300000,"profit":false},{"date":"2021-12-31","value":-2496400000,"profit":false},{"date":"2022-12-31","value":-3410400000,"profit":false},{"date":"2023-12-31","value":-5192000000,"profit":false},{"date":"2024-12-31","value":-4212100000,"profit":false}]
Total Non-Operating Income/Expense356.00K380.00K2.17M5.83M7.76M[{"date":"2020-12-31","value":4.59,"profit":true},{"date":"2021-12-31","value":4.9,"profit":true},{"date":"2022-12-31","value":28.03,"profit":true},{"date":"2023-12-31","value":75.15,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(22.21M)(24.77M)(33.02M)(48.82M)(38.24M)[{"date":"2020-12-31","value":-2221500000,"profit":false},{"date":"2021-12-31","value":-2477400000,"profit":false},{"date":"2022-12-31","value":-3301700000,"profit":false},{"date":"2023-12-31","value":-4881800000,"profit":false},{"date":"2024-12-31","value":-3824300000,"profit":false}]
Income Taxes(178.00K)(190.00K)(1.09M)622.11K-[{"date":"2020-12-31","value":-28.61,"profit":false},{"date":"2021-12-31","value":-30.54,"profit":false},{"date":"2022-12-31","value":-174.73,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(22.04M)(24.58M)(31.93M)(49.44M)-[{"date":"2020-12-31","value":-2203700000,"profit":false},{"date":"2021-12-31","value":-2458400000,"profit":false},{"date":"2022-12-31","value":-3193000000,"profit":false},{"date":"2023-12-31","value":-4944010500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(22.21M)(24.77M)(33.02M)(50.14M)(38.24M)[{"date":"2020-12-31","value":-2221500000,"profit":false},{"date":"2021-12-31","value":-2477400000,"profit":false},{"date":"2022-12-31","value":-3301700000,"profit":false},{"date":"2023-12-31","value":-5014100000,"profit":false},{"date":"2024-12-31","value":-3824300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(22.04M)(24.58M)(31.93M)(48.82M)(38.24M)[{"date":"2020-12-31","value":-2203700000,"profit":false},{"date":"2021-12-31","value":-2458400000,"profit":false},{"date":"2022-12-31","value":-3193000000,"profit":false},{"date":"2023-12-31","value":-4881800000,"profit":false},{"date":"2024-12-31","value":-3824300000,"profit":false}]
EPS (Diluted)(2.04)(1.20)(1.37)(1.84)(1.27)[{"date":"2020-12-31","value":-204,"profit":false},{"date":"2021-12-31","value":-120,"profit":false},{"date":"2022-12-31","value":-137,"profit":false},{"date":"2023-12-31","value":-184,"profit":false},{"date":"2024-12-31","value":-127,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ATNM
Cash Ratio 8.95
Current Ratio 9.14

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ATNM
ROA (LTM) -33.25%
ROE (LTM) -110.63%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ATNM
Debt Ratio Lower is generally better. Negative is bad. 0.57
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.43

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ATNM
Trailing PE NM
Forward PE 6.84
P/S (TTM) 652.71
P/B 1.14
Price/FCF NM
EV/R 1726.07
EV/Ebitda NM
PEG NM

FAQs

What is Actinium Pharmaceuticals Inc share price today?

Actinium Pharmaceuticals Inc (ATNM) share price today is $1.38

Can Indians buy Actinium Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Actinium Pharmaceuticals Inc (ATNM) on Vested. To buy Actinium Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ATNM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Actinium Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Actinium Pharmaceuticals Inc (ATNM) via the Vested app. You can start investing in Actinium Pharmaceuticals Inc (ATNM) with a minimum investment of $1.

How to invest in Actinium Pharmaceuticals Inc shares from India?

You can invest in shares of Actinium Pharmaceuticals Inc (ATNM) via Vested in three simple steps:

  • Click on Sign Up or Invest in ATNM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Actinium Pharmaceuticals Inc shares
What is Actinium Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Actinium Pharmaceuticals Inc (ATNM) is $10.24. The 52-week low price of Actinium Pharmaceuticals Inc (ATNM) is $1.03.

What is Actinium Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Actinium Pharmaceuticals Inc (ATNM) is 1.14

What is the Market Cap of Actinium Pharmaceuticals Inc?

The market capitalization of Actinium Pharmaceuticals Inc (ATNM) is $39.31M

What is Actinium Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Actinium Pharmaceuticals Inc is ATNM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top